Quantcast

Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD

November 15, 2010

JERUSALEM, November 15, 2010 /PRNewswire-FirstCall/ — Oramed
Pharmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of
oral drug delivery systems, presented the results of its recently completed
Phase IIb trial. The multicenter, placebo-controlled, randomized,
double-blind study conducted in 29 patients with Type II diabetes assessed
the safety of ORMD-0801 in patients with Type II diabetes. Results were
presented by the company’s Chief Scientific Officer, Dr. Miriam Kidron, at
the Tenth Annual Meeting of the Diabetes Technology Society, in Bethesda,
Maryland
.

The poster presentation entitled “Extended exposure to an oral insulin
formulation yields decreased insulin secretion in Type II diabetes subjects,”
described Oramed’s first extended exposure study to its oral insulin product
(ORMD-0801), where 21 patients were treated with ORMD-0801, self-administered
daily for a period of six weeks. In parallel, a group of eight patients
received placebo capsules administered under the same treatment regimen.
ORMD-0801 proved safe and tolerable, with no reports of serious adverse
events throughout the study. In addition, no cumulative effects of extended
ORMD-0801 exposure were noted, and only two mild cases of transient
hypoglycemia were reported. Treatment efficacy was evaluated via markers
quantified from blood samples drawn at the start and end of the study. Daily
administration of oral insulin led to a statistically significant decrease in
both insulin and C-reactive protein (CRP) levels, in contrast to their
elevation among placebo-treated individuals. Moreover, the percentage of
subjects demonstrating clinically relevant reductions in insulin, c-peptide,
fasting blood glucose (FBG) and Hb1Ac levels was consistently higher in the
ORMD-0801 cohort, when compared to its placebo counterpart. This study
addressing, for the first time, potential long-term safety concerns from
extended ORMD-0801 administrations, demonstrated safety and no serious
adverse events were reported.

The poster can be viewed at: http://www.oramed.com/index.php?page=13

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
Phase 2 clinical trials. Established in 2006, Oramed’s technology is based on
over 25 years of research performed by top research scientists at Jerusalem’s
Hadassah Medical Center. The Company’orporate and R&D headquarters are based
in Jerusalem.

For more information, please visit http://www.oramed.com

Safe Harbor Statement

Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks
and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company’s ability to
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of the company
to differ materially from those expressed or implied in such forward looking
statements. The company undertakes no obligation to update or revise any
forward-looking statements.

    Company and Investor Relation Contacts:
    Oramed Pharmaceuticals
    Tara Horn
    Cell: +972-54-334-318
    Office: +972-2-566-0001
    Email: tara@oramed.com

SOURCE Oramed Pharmaceuticals Inc.


Source: newswire



comments powered by Disqus